New hope to stop dangerous transplant complication
NCT ID NCT02891603
Summary
This study tested if adding a drug called pacritinib to standard anti-rejection medicines could better prevent graft-versus-host disease (GVHD) after a stem cell transplant. It involved 40 patients with blood cancers who received matched donor transplants. Researchers measured inflammation levels and tracked whether patients developed GVHD to see if the three-drug combination was more effective.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT VS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.